Why the study?
Does encainide suppress premature ventricular complexes in patients with chronic ventricular arrhythmias?
Population
9 patients with frequent and complex premature ventricular complexes
Comparison
Encainide 75 mg i.v. or oral vs Placebo
Design
RCT, double-blind
Follow-up
3 days
Authors
Loading...
Encainide achieves high PVC suppression rates; supports evaluation for chronic oral dosing in ventricular arrhythmias.
Does encainide suppress premature ventricular complexes in patients with chronic ventricular arrhythmias?
Encainide effectively suppresses ventricular arrhythmias and exhibits a wide ratio of toxic to therapeutic concentration, suggesting suitability for chronic oral dosing.
Winkle et al. (1981) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: